Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study
MDM Policy & Practice · 2021-01 · 6 (1)
DOI: 10.1177/2381468320978407 ↗Kurz gefasst
Fachartikel in der Zeitschrift MDM Policy & Practice, online erschienen am 18.01.2021. Verfasst von Brett Hauber und 16 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Research Triangle Park, North Carolina. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Device Innovation Consortium.
Abstract (Originalsprache)
Background
Parkinson’s disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients’ preferences for novel neurostimulation devices may help ensure that devices are delivered in a timely manner with the appropriate level of evidence. Our objective was to elicit preferences and willingness-to-wait for novel neurostimulation devices among PD patients to inform a model of optimal trial design.
Methods
We developed and administered a survey to PD patients to quantify the maximum levels of risks that patients would accept to achieve potential benefits of a neurostimulation device. Threshold technique was used to quantify patients’ risk thresholds for new or worsening depression or anxiety, brain bleed, or death in exchange for improvements in “on-time,” motor symptoms, pain, cognition, and pill burden. The survey elicited patients’ willingness to wait to receive treatment benefit. Patients were recruited through Fox Insight, an online PD observational study.
Results
A total of 2740 patients were included and a majority were White (94.6%) and had a 4-year college degree (69.8%). Risk thresholds increased as benefits increased. Threshold for depression or anxiety was substantially higher than threshold for brain bleed or death. Patient age, ambulation, and prior neurostimulation experience influenced risk tolerance. Patients were willing to wait an average of 4 to 13 years for devices that provide different levels of benefit.
Conclusions
PD patients are willing to accept substantial risks to improve symptoms. Preferences are heterogeneous and depend on treatment benefit and patient characteristics. The results of this study may be useful in informing review of device applications and other regulatory decisions and will be input into a model of optimal trial design for neurostimulation devices.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- RTI Health Solutions, Research Triangle Park, North Carolina.
- FDA Center for Devices and Radiological Health, Silver Spring, Maryland.
- MIT Sloan School of Management, Cambridge, Massachusetts.
- Medical Device Innovation Consortium, Arlington, Virginia.
- The Michael J. Fox Foundation for Parkinson's Research, Patient Council, New York, New York.
- The Michael J. Fox Foundation for Parkinson's Research, New York, New York.
ORCID-Profile: Brett Hauber, Heather L Benz, Anindita Saha
Förderung
- Medical Device Innovation Consortium
Zitieren
APA
Hauber, B., Mange, B., Zhou, M., Chaudhuri, S., Benz, H. L., Caldwell, B., Ruiz, J. P., Saha, A., Ho, M., Christopher, S., Bardot, D., Sheehan, M., Donnelly, A., McLaughlin, L., Gwinn, K., Lo, A., & Sheldon, M. (2021). Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study. MDM Policy & Practice, 6(1). https://doi.org/10.1177/2381468320978407
Vancouver
Hauber B, Mange B, Zhou M, Chaudhuri S, Benz HL, Caldwell B, et al. Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study. MDM Policy & Practice. 2021;6(1). doi:10.1177/2381468320978407
BibTeX
@article{Hauber2021,
author = {Hauber, Brett and Mange, Brennan and Zhou, Mo and Chaudhuri, Shomesh and Benz, Heather L and Caldwell, Brittany and Ruiz, John P and Saha, Anindita and Ho, Martin and Christopher, Stephanie and Bardot, Dawn and Sheehan, Margaret and Donnelly, Anne and McLaughlin, Lauren and Gwinn, Katrina and Lo, Andrew and Sheldon, Murray},
title = {Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study},
journal = {MDM Policy & Practice},
year = {2021},
volume = {6},
number = {1},
doi = {10.1177/2381468320978407}
}
EUVIMED